EA200201183A1 - Новые полициклические соединения и их применение - Google Patents

Новые полициклические соединения и их применение

Info

Publication number
EA200201183A1
EA200201183A1 EA200201183A EA200201183A EA200201183A1 EA 200201183 A1 EA200201183 A1 EA 200201183A1 EA 200201183 A EA200201183 A EA 200201183A EA 200201183 A EA200201183 A EA 200201183A EA 200201183 A1 EA200201183 A1 EA 200201183A1
Authority
EA
Eurasian Patent Office
Prior art keywords
connections
application
new polycyclic
new
activity
Prior art date
Application number
EA200201183A
Other languages
English (en)
Other versions
EA007868B1 (ru
Inventor
Марк А. Атор
Рон Биховски
Санкар Чаттерджи
Дерек Данн
Роберт Л. Хадкинс
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of EA200201183A1 publication Critical patent/EA200201183A1/ru
Publication of EA007868B1 publication Critical patent/EA007868B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Данное изобретение относится к новым полициклическим молекулам, которые опосредуют ферментативную активность. В частности, эти соединения могут быть эффективными в лечении заболеваний или патологических состояний, связанных с активностью ферментов PARP, VEGFR2 и MLK3, в том числе, например, нейродегенеративных заболеваний, воспаления, ишемии и рака.Отчет о международном поиске был опубликован 2002.05.30.
EA200201183A 2000-05-09 2001-05-09 Новые полициклические соединения и их применение EA007868B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20294700P 2000-05-09 2000-05-09
US09/850,858 US7122679B2 (en) 2000-05-09 2001-05-08 Multicyclic compounds and the use thereof
PCT/US2001/014996 WO2001085686A2 (en) 2000-05-09 2001-05-09 Multicyclic compounds and the use as inhibitors of parp, vegfr2 and mlk3 enzymes

Publications (2)

Publication Number Publication Date
EA200201183A1 true EA200201183A1 (ru) 2003-06-26
EA007868B1 EA007868B1 (ru) 2007-02-27

Family

ID=26898160

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201183A EA007868B1 (ru) 2000-05-09 2001-05-09 Новые полициклические соединения и их применение

Country Status (28)

Country Link
US (1) US7122679B2 (ru)
EP (3) EP2050750B1 (ru)
JP (1) JP5156150B2 (ru)
KR (1) KR100832602B1 (ru)
CN (2) CN100554268C (ru)
AT (3) ATE411997T1 (ru)
AU (1) AU6132701A (ru)
BG (1) BG66036B1 (ru)
BR (1) BR0110993A (ru)
CA (1) CA2409758A1 (ru)
CY (1) CY1108722T1 (ru)
CZ (2) CZ305350B6 (ru)
DE (3) DE60143140D1 (ru)
DK (1) DK1754707T3 (ru)
EA (1) EA007868B1 (ru)
ES (2) ES2315789T3 (ru)
HK (3) HK1051369A1 (ru)
HU (1) HU229448B1 (ru)
IL (1) IL152663A0 (ru)
MX (1) MXPA02010977A (ru)
NO (1) NO324256B1 (ru)
NZ (1) NZ522539A (ru)
PL (1) PL226805B1 (ru)
PT (1) PT1754707E (ru)
SK (1) SK287591B6 (ru)
UA (1) UA73773C2 (ru)
WO (1) WO2001085686A2 (ru)
ZA (1) ZA200209065B (ru)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US20060276497A1 (en) * 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2002354499A1 (en) * 2001-12-18 2003-06-30 Kyowa Hakko Kogyo Co., Ltd. Indole derivative
US7094798B1 (en) 2002-04-26 2006-08-22 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
WO2003091255A1 (en) * 2002-04-26 2003-11-06 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7511065B2 (en) 2003-11-12 2009-03-31 Eli Lilly And Company Mixed lineage kinase modulators
JP5545690B2 (ja) 2003-12-01 2014-07-09 クドス ファーマシューティカルズ リミテッド 癌治療のためのｄｎａ損傷修復阻害剤
CN1905864B (zh) * 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
CA2564952A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
SG164368A1 (en) * 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
KR20100132087A (ko) * 2005-09-02 2010-12-16 오츠카 세이야쿠 가부시키가이샤 벤즈아제핀 화합물 또는 그의 염의 제조 방법
ATE536349T1 (de) * 2005-09-29 2011-12-15 Abbott Lab In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
WO2008030883A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
PT2086525E (pt) * 2006-11-20 2010-12-09 Cephalon Inc Método de radiossensibilização de tumores utilizando um radiossensibilizador
EP2167075A4 (en) * 2007-06-08 2012-07-11 Univ Massachusetts MIXED LINEAGE KINASES AND METABOLISM DISORDER
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CN102083314B (zh) 2007-10-03 2014-04-30 卫材股份有限公司 Parp抑制剂化合物、组合物以及使用方法
US20090149417A1 (en) * 2007-10-19 2009-06-11 Valeria Ossovskaya Methods and compositions for the treatment of cancer using benzopyrone-type PARP inhibitors
US20090123419A1 (en) * 2007-11-12 2009-05-14 Bipar Sciences Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
SG185952A1 (en) * 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CN101999002A (zh) * 2008-02-04 2011-03-30 彼帕科学公司 诊断和治疗parp-介导的疾病的方法
JP2010006717A (ja) * 2008-06-24 2010-01-14 Kyorin Pharmaceut Co Ltd ジヒドロチエノ［２，３−ｅ］インダゾール化合物
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
WO2010082813A1 (en) 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
ES2572652T3 (es) 2009-08-26 2016-06-01 Cephalon, Inc. Nuevas formas de un compuesto multicíclico
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011077502A1 (ja) * 2009-12-21 2011-06-30 杏林製薬株式会社 ジヒドロチエノ［２，３－ｅ］インダゾール化合物
US8999985B2 (en) 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
US9771325B2 (en) 2014-02-14 2017-09-26 Council Of Scientific & Industrial Research Tricyclic compounds and preparation thereof
WO2015121876A1 (en) * 2014-02-14 2015-08-20 Council Of Scientific & Industrial Research Novel tricyclic compounds and preparation thereof
AU2015353549A1 (en) 2014-11-26 2017-06-01 Cephalon, Inc. Crystalline forms of PARP inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3325623B3 (en) 2015-07-23 2021-01-20 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
SG11201903842YA (en) 2016-11-02 2019-05-30 Immunogen Inc Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
EP4079726A4 (en) 2019-12-16 2024-01-24 Korea Res Inst Chemical Tech NEW PYRIMIDINE DERIVATIVE AND CORRESPONDING USE
US20230348399A1 (en) 2019-12-16 2023-11-02 Korea Research Institute Of Chemical Technology Novel pyrimidine derivative and use thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113636970B (zh) * 2021-09-13 2023-05-23 河北康泰药业有限公司 一种异吲哚酮的化合物、制备方法及其应用
KR20230155351A (ko) 2022-05-03 2023-11-10 한국화학연구원 5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
DE3833008A1 (de) * 1988-09-29 1990-04-05 Goedecke Ag Pyrrolocarbozol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5166204A (en) * 1989-11-01 1992-11-24 Toyama Chemical Co., Ltd. Isoindole derivatives and salts thereof and antitumor agent comprising the same
JP3025536B2 (ja) 1990-12-27 2000-03-27 富山化学工業株式会社 新規なカルバゾール誘導体およびその塩
JPH06507392A (ja) 1991-02-26 1994-08-25 エイアールシー　１，インコーポレイテッド 交感神経性の持続性疼痛の治療のための組成物および方法
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
GB9319297D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
EP0695755B1 (en) 1994-08-04 1998-10-21 F. Hoffmann-La Roche AG Pyrrolocarbazole
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
DE69629341T2 (de) 1995-03-09 2004-06-09 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazolderivate
DK0971717T3 (da) * 1996-08-22 2002-03-25 Bristol Myers Squibb Co Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
WO1998009967A1 (fr) 1996-09-09 1998-03-12 Kyowa Hakko Kogyo Co., Ltd. Derives de pyrrolocarbazole
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
AU748887B2 (en) 1998-02-12 2002-06-13 Myriad Genetics, Inc. Beta-sheet mimetics and methods relating to the use thereof
AU758241B2 (en) 1998-03-13 2003-03-20 University Of British Columbia, The Granulatimide derivatives for use in cancer treatment
WO1999059975A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
US6063803A (en) * 1998-06-16 2000-05-16 Ortho-Mcneil Pharmaceutical, Inc. Octahydropyrrolo-[3,4-c]carbazoles useful as analgesic agents
TR200400635T2 (tr) * 1998-08-26 2005-10-21 Cephalon, Inc. Çok nesilli kinaz proteinlerin modüle edilmesi
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
EP2050750A2 (en) 2009-04-22
CZ20023679A3 (cs) 2003-10-15
JP5156150B2 (ja) 2013-03-06
UA73773C2 (ru) 2005-09-15
CN101560213B (zh) 2011-01-19
CN1440409A (zh) 2003-09-03
WO2001085686A2 (en) 2001-11-15
PL226805B1 (pl) 2017-09-29
ATE411997T1 (de) 2008-11-15
ATE315039T1 (de) 2006-02-15
EP1294725B1 (en) 2006-01-04
NO20025376L (no) 2003-01-08
EP2050750A3 (en) 2009-07-08
CN100554268C (zh) 2009-10-28
CZ305350B6 (cs) 2015-08-12
HK1129381A1 (en) 2009-11-27
SK287591B6 (sk) 2011-03-04
DE60116485T2 (de) 2006-11-09
DE60136305D1 (de) 2008-12-04
ATE482215T1 (de) 2010-10-15
KR100832602B1 (ko) 2008-05-27
MXPA02010977A (es) 2003-07-14
NZ522539A (en) 2004-05-28
PL363167A1 (en) 2004-11-15
ES2315789T3 (es) 2009-04-01
CA2409758A1 (en) 2001-11-15
DE60116485D1 (de) 2006-03-30
SK15802002A3 (sk) 2003-05-02
BR0110993A (pt) 2003-06-24
BG66036B1 (bg) 2010-11-30
EP1294725A2 (en) 2003-03-26
CZ304911B6 (cs) 2015-01-21
CN101560213A (zh) 2009-10-21
NO20025376D0 (no) 2002-11-08
US20020028815A1 (en) 2002-03-07
PT1754707E (pt) 2008-12-12
DK1754707T3 (da) 2008-12-15
HUP0302385A2 (hu) 2003-12-29
JP2004501097A (ja) 2004-01-15
EP1754707A3 (en) 2007-02-28
KR20030007603A (ko) 2003-01-23
IL152663A0 (en) 2003-06-24
ES2256238T3 (es) 2006-07-16
HU229448B1 (en) 2013-12-30
EA007868B1 (ru) 2007-02-27
BG107355A (bg) 2003-07-31
ZA200209065B (en) 2004-02-09
HK1097841A1 (en) 2007-07-06
HK1051369A1 (en) 2003-08-01
HUP0302385A3 (en) 2007-03-28
EP2050750B1 (en) 2010-09-22
EP1754707B1 (en) 2008-10-22
US7122679B2 (en) 2006-10-17
NO324256B1 (no) 2007-09-17
EP1754707A2 (en) 2007-02-21
DE60143140D1 (de) 2010-11-04
CY1108722T1 (el) 2014-04-09
AU6132701A (en) 2001-11-20
WO2001085686A3 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
EA200201183A1 (ru) Новые полициклические соединения и их применение
CY1114153T1 (el) Παραγωγα κυκλοαλκανοπυρρολοκαρβαzολιου και η χρηση αυτων ως αναστολεις parp, vegfr2 και mlk3
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
EA200001245A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ ПИРРОЛО [2,3d] ПИРИМИДИНОВ И ИХ ПРИМЕНЕНИЕ
TR200102817T2 (tr) Antiinflamatuar ajanlar olarak faydalı bileşikler
MA31167B1 (fr) Inhibiteurs de l'activite de akt
TR199701073T1 (xx) Protein kinaz C inhibit�rleri.
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
EA200100278A1 (ru) Способы модулирования киназных белков множественных линий и скрининга соединений, которые модулируют киназные белки множественных линий
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
WO2001042784A3 (en) Methods for screening compounds active on neurons
ATE420636T1 (de) Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DK1314040T3 (da) Anvendelse af GRF1-protein til screening af molekyler
ATE323289T1 (de) Auf tsap6-bindungspartnern beruhendes screeningverfahren
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU